Pediatric Research May Be Hurt By Lack Of FDA-EMA Harmonization
Executive Summary
Differences between U.S. and European laws regarding pediatric studies also may be creating a disincentive for completing the research, according to information in a Government Accountability Office report.
You may also be interested in...
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
The regular reauthorization of PREA and BPCA, when coupled with the long review horizon for pediatric studies at FDA, could be hindering sponsors’ willingness to conduct the trials, according to a Government Accountability Office Report.
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
The regular reauthorization of PREA and BPCA, when coupled with the long review horizon for pediatric studies at FDA, could be hindering sponsors’ willingness to conduct the trials, according to a Government Accountability Office Report.
FDA-EMA-TGA Joint Inspection Program To Be Permanent; Other Collaborations Expand
FDA, the European Medicines Agency and Australian Therapeutic Goods Administration intend to make permanent a pilot program allowing for joint facility inspections in what would be another step toward more U.S. reliance on foreign regulator and third-party data and a reduction in inspection burden.